Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3515320 | 0.88 | CYP11B1 (0.41) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL4768617 | 0.86 | ADRA2A (0.39) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL506458 | 0.82 | — | — | |
| SCHEMBL23497624 | 0.81 | ALDH1A1 (0.36) | GBA1ALDH1A1KDM4ETSHRRAB9A | |
| SCHEMBL21552702 | 0.80 | GBA1 (0.44) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL7433897 | 0.78 | GBA1 (0.42) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL3231706 | 0.78 | GBA1 (0.52) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL20802798 | 0.78 | GBA1 (0.42) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL31729646 | 0.78 | GBA1 (0.52) | GBA1ALDH1A1KDM4EADRA2AADRA2B | |
| SCHEMBL5674 | 0.78 | GBA1 (0.42) | GBA1ALDH1A1KDM4EADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | ASTRAZENECA AB (SE) | 2025-09-02 | — | — | US | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-120077035-A | As CX32,4, 6-Trisubstituted 1,3, 5-triazines as modulators of CR1 | 阿斯利康(瑞典)有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-119101069-A | Spiro compounds and uses thereof | 轩竹生物科技股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | ASTRAZENECA AB (SE) | 2024-11-21 | — | — | US | disclosed |
| CN-114555604-B | Pharmaceutical compounds | 辉瑞公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| EP-4457230-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene Switzerland GmbH (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| CN-102260277-A | Novel benzoxazine oxazolidinone compound and preparation method and application thereof | — | 2011-11-30 | — | — | CN | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
| US-20110137032-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2311822-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2011-04-20 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383866-A1 | 2,4,6-TRISUBSTITUTED 1,3,5-TRIAZINES AS MODULATORS OF CX3CR1 | CX3CR1, CCR2, CCR5 | GBA1 2322/4885ALDH1A1 1531/4885KDM4E 4608/4885 |
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | GBA1 3034/4885ALDH1A1 3480/4885KDM4E 4162/4885 |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | GBA1 491/4885ALDH1A1 2127/4885KDM4E 1331/4885 |
| US-12404253-B2 | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | CX3CR1, CCR2, CCR5 | GBA1 2322/4885ALDH1A1 1531/4885KDM4E 4608/4885 |
| US-20240366770-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | GBA1 2604/4885ALDH1A1 4351/4885KDM4E 983/4885 |
| US-20110137032-A1 | GPR119 AGONIST | GPR119, GPR27, GPR52 | GBA1 3066/4885ALDH1A1 3105/4885KDM4E 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.